Josephine Wells

Learn More
The vasoconstrictive peptide endothelin-1 (ET-1) has been used previously to transiently occlude the middle cerebral artery (MCA) in rats. However, the duration of the resulting reduction in cerebral blood flow (CBF) and the reperfusion characteristics are poorly understood. In this study perfusion and T(2)-weighted MRI were used together with histology to(More)
Previous reports have suggested that "endogenous" benzodiazepines could contribute to neural inhibition in hepatic encephalopathy. RO 15-1788 (flumazenil), a specific antagonist of brain benzodiazepine receptors, could thus reverse the neurological symptoms of hepatic encephalopathy. To test this possibility, we conducted a double-blind, placebo-controlled(More)
4091 Background: Despite trimodality therapy the prognosis for LAEC is poor. Adjuvant anti-VEGF strategies are under study in many cancers. In this completed phase II trial we report tolerability and efficacy of Su, a multitargeted tyrosine kinase inhibitor, following chemoradiation and surgery for LAEC. METHODS Included were patients (pts) with LAEC of(More)
The prognosis for locally advanced esophageal cancer is poor despite the use of trimodality therapy. In this phase II study, we report the feasibility, tolerability and efficacy of adjuvant sunitinib. Included were patients with stage IIa, IIB or III cancer of the thoracic esophagus or gastroesophageal junction. Neoadjuvant therapy involved Irinotecan (65(More)
The records of 427 patients with gastric cancer have been reviewed and the various types of X-ray abnormalities produced by the tumor have been correlated with the clinical course following surgery. The 5-year survival rate for the entire series was 11 per cent. Patients with X-ray evidence of an ulcer of the pars media without a mass had superior follow-up(More)
3016 Background: Malignant transformation and invasiveness correlate with upregulation of N-cad, a cell adhesion molecule expressed on tumor cells and vascular endothelium. N-cad antagonism by ADH-1, a cyclic pentapeptide (CHAVC), causes rapid tumor vascular disruption and apoptosis in preclinical models. We report the final clinical and PK results from the(More)